Abaloparatide - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for abaloparatide and what is the scope of patent protection?
Abaloparatide
is the generic ingredient in one branded drug marketed by Radius Health Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Abaloparatide has fifty patent family members in twenty-six countries.
One supplier is listed for this compound.
Summary for abaloparatide
International Patents: | 50 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 14 |
Drug Prices: | Drug price trends for abaloparatide |
What excipients (inactive ingredients) are in abaloparatide? | abaloparatide excipients list |
DailyMed Link: | abaloparatide at DailyMed |
Recent Clinical Trials for abaloparatide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Daniel Horwitz | Phase 4 |
Johns Hopkins University | Phase 2 |
Crozer-Keystone Health System | Phase 4 |
Pharmacology for abaloparatide
Drug Class | Parathyroid Hormone-Related Peptide Analog |
Anatomical Therapeutic Chemical (ATC) Classes for abaloparatide
US Patents and Regulatory Information for abaloparatide
EU/EMA Drug Approvals for abaloparatide
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Radius International Ltd | Eladynos | abaloparatide | EMEA/H/C/004157 Treatment of osteoporosis. |
Refused | no | no | no | 2019-01-07 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for abaloparatide
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20210120009 | 부갑상선 호르몬(PTH) 및 부갑상선 호르몬-관련 펩티드(PTHRP) 유사체에 대한 중화 항체의 검출 방법 | See Plans and Pricing |
China | 101578093 | Method of drug delivery for bone anabolic protein | See Plans and Pricing |
European Patent Office | 3908605 | PROCÉDÉS DE DÉTECTION D'ANTICORPS DE NEUTRALISATION DIRIGÉS CONTRE L'HORMONE PARATHYROÏDE (PTH) ET ANALOGUE DE PEPTIDE LIÉ À L'HORMONE PARATHYROÏDE (PTHRP) (METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG) | See Plans and Pricing |
Portugal | 2073789 | See Plans and Pricing | |
Australia | 2020207653 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog | See Plans and Pricing |
Japan | 2010505835 | See Plans and Pricing | |
Portugal | 2957278 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.